One of the antihyperglycemic pharmacologic agents that has proven pleiotropic beneficial effects are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that, alongside their efficacy in improving glycemic control, without an additional risk of hypoglycemia, by increasing the secretion of insulin and reducing the secretion of glucagon in a manner dependent on blood glucose levels, contribute to weight loss through reducing appetite, increasing satiety, and delaying gastric emptying. The gene discussed is GLP1R; the disease is Hypoglycemia.